Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Unknown 15Completed 13Recruiting 10Active not recruiting 5Terminated 4Withdrawn 3Suspended 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 158Pancreatic Neoplasms 148Carcinoma, Hepatocellular 127Colonic Neoplasms 79Stomach Neoplasms 58Rectal Neoplasms 58Liver Neoplasms 47Esophageal Neoplasms 46Breast Neoplasms 40Neoplasms 36Neoplasm Metastasis 35Cholangiocarcinoma 32Lung Neoplasms 23Gastrointestinal Neoplasms 20Ovarian Neoplasms 17Biliary Tract Neoplasms 15Carcinoma, Non-Small-Cell Lung 14Esophageal Squamous Cell Carcinoma 13Uterine Cervical Neoplasms 11Gallbladder Neoplasms 10Adenocarcinoma 10Sarcoma 9Carcinoma, Renal Cell 9Adenocarcinoma Of Esophagus 9Urinary Bladder Neoplasms 8Recurrence 8Bile Duct Neoplasms 8Prostatic Neoplasms 7Gastrointestinal Stromal Tumors 7Colonic Polyps 7

Interventions

sonidegib 1devimistat 1PEGPH20 1Gemcitabine 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Pancreatic Ductal Adenocarcinoma × Gastrointestinal × Clear all
NCT03374852 2025-04-29

CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer

Thomas Jefferson University

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT04134468 2020-01-31

MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma

Abramson Cancer Center at Penn Medicine

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT01911416 2016-06-09

A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer

University of Utah

Phase NA Withdrawn
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡